Inactive Instrument

Paratek Pharmaceuticals, Inc.

PRTK

US6993743029

Novo Holdings closes $462 million acquisition of Paratek Pharmaceuticals

September 21, 2023 at 12:30 pm EDT

COPENHAGEN (Reuters) - Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk, on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 million.

The acquisition of Paratek Pharmaceuticals, which was announced in early June, is Novo Holdings' largest individual investment in antimicrobial resistance therapies to date, it said in a statement.

Novo Holdings, which controls 76% of the votes in Denmark's Novo Nordisk last week announced a major investment in a new energy transition fund, as it is looking to expand its portfolio beyond health.

(Reporting by Louise Breusch Rasmussen, editing by Jane Merriman)

Latest news about Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals Announces Positive Efficacy Data for Nuzyra® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement Under Barda Project Bioshield Contract	Mar. 05	CI
Paratek Pharmaceuticals, Inc. Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer	Jan. 16	CI
Paratek Pharmaceuticals, Inc. Promotes Christopher Bostrom to Chief Financial Officer	Jan. 16	CI
Novo Holdings, Gurnet Point Close $462 Million Purchase of Paratek Pharmaceuticals	23-09-22	MT
Novo Holdings closes $462 million acquisition of Paratek Pharmaceuticals	23-09-21	RE
Paratek Pharmaceuticals, Inc. Announces Board Changes	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from NASDAQ Composite Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P TMI Index	23-09-21	CI
Gurnet Point Capital Limited and Novo Holdings A/S acquired acquire Paratek Pharmaceuticals, Inc. from a group of shareholders.	23-09-20	CI
Paratek Pharmaceuticals Says Shareholders Approved $462 Million Acquisition by Gurnet Point Capital, Novo Holdings	23-09-18	MT
Paratek Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Reports Q2 Revenue $40M	23-08-03	MT
Paratek Pharmaceuticals' Investor NexPoint Sends Demand Letter for Records of Proposed Takeover by Gurnet	23-07-11	MT
Declaration of Voting Results by Paratek Pharmaceuticals	23-07-11	CI
Paratek Modifies Contract With US Government's BARDA to Advance Nuzyra Antibiotic	23-07-10	MT
Paratek Pharmaceuticals, Inc. Announces Modification of Barda Contract to Advance the Development of NuzyraÂ®? (Omadacycline) for Post-Exposure Prophylaxis and Treatment of Pulmonary Anthrax	23-07-10	CI
Paratek Pharmaceuticals Says 'Disagrees' With NexPoint Asset Management's Accusations	23-06-27	MT
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Advisors Letter	23-06-27	CI
Paratek Pharmaceuticals' NUZYRA Therapy for Nontuberculous Mycobacterial Lung Disease Gets EU Positive Opinion	23-06-27	MT
NexPoint Advisors Sends a Letter to Paratek Pharmaceuticals	23-06-27	CI
Paratek Pharmaceuticals, Inc. Presents New Data from NUZYRA®? (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023	23-06-12	CI
North American Morning Briefing : Nasdaq Futures -2-	23-06-08	DJ
HC Wainwright Downgrades Paratek Pharmaceuticals to Neutral From Buy, Price Target is $2.15	23-06-07	MT
Jefferies Downgrades Paratek Pharmaceuticals to Hold From Buy, Adjusts Price Target to $2.15 From $5	23-06-07	MT

Chart Paratek Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.

Sector

Pharmaceuticals

Calendar

07:00am - European Society of Clinical Microbiology & Infectious Diseases Global Conference - Abstract Number

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals